IUPAC/Chemical Name
1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)(2-hydroxyethyl)amino)-2,4,6-triiodo-
InChi Key
AMDBBAQNWSUWGN-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33)
SMILES Code
O=C(C1=C(I)C(N(C(CO)=O)CCO)=C(I)C(C(NCC(O)CO)=O)=C1I)NCC(O)CO
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
807.12
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Ioversol. 2018 Oct 31. PMID: 30000462.
2: Tan Y, Zheng S, Lei W, Wang F, Jiang S, Zeng T, Zhou B, Hong F. Ethiodized poppyseed oil versus ioversol for image quality and adverse events in hysterosalpingography: a prospective cohort study. BMC Med Imaging. 2019 Jun 24;19(1):50. doi: 10.1186/s12880-019-0346-0. PMID: 31234782; PMCID: PMC6591817.
3: Wang H, Li T, Zhao L, Sun M, Jian Y, Liu J, Zhang Y, Li Y, Dang M, Zhang G. Dynamic Effects of Ioversol on the Permeability of the Blood-Brain Barrier and the Expression of ZO-1/Occludin in Rats. J Mol Neurosci. 2019 Jun;68(2):295-303. doi: 10.1007/s12031-019-01305-z. Epub 2019 Apr 7. PMID: 30955191.
4: Quirós C, Cillero AI, Bretaña L, García M, Prieto B, Álvarez FV. In vivo interference of Ioversol in serum and urine capillary electrophoresis: an optimized protocol for sample collection. Clin Chem Lab Med. 2018 Jan 26;56(2):e53-e55. doi: 10.1515/cclm-2017-0509. PMID: 28771431.
5: Hammerbeck AA, Daniels NH, Callen JP. Ioversol-induced acute generalized exanthematous pustulosis: a case report. Arch Dermatol. 2009 Jun;145(6):683-7. doi: 10.1001/archdermatol.2009.100. PMID: 19528424.
6: Scott H, Palmer FJ. Ioversol in ascending phlebography--a clinical trial. Australas Radiol. 1990 Feb;34(1):44-6. doi: 10.1111/j.1440-1673.1990.tb02806.x. PMID: 2192700.
7: Vogl TJ, Wessling J, Buerke B. An observational study to evaluate the efficiency and safety of ioversol pre-filled syringes compared with ioversol bottles in contrast-enhanced examinations. Acta Radiol. 2012 Oct 1;53(8):914-20. doi: 10.1258/ar.2012.120303. Epub 2012 Sep 14. PMID: 22983259.
8: Morales-Cabeza C, Roa-Medellín D, Torrado I, De Barrio M, Fernández-Álvarez C, Montes-Aceñero JF, De La Riva I, Prieto-García A. Immediate reactions to iodinated contrast media. Ann Allergy Asthma Immunol. 2017 Dec;119(6):553-557. doi: 10.1016/j.anai.2017.08.014. Epub 2017 Oct 7. PMID: 29017901.
9: Oldroyd SD, Haylor JL, Morcos SK. The acute effect of ioversol on kidney function: role of endothelin. Eur J Radiol. 1995 Jan;19(2):91-5. doi: 10.1016/0720-048x(94)00579-2. PMID: 7713094.
10: Suh YJ, Yoon SH, Hong H, Hahn S, Kang DY, Kang HR, Choi YH, Lee W. Acute Adverse Reactions to Nonionic Iodinated Contrast Media: A Meta-Analysis. Invest Radiol. 2019 Sep;54(9):589-599. doi: 10.1097/RLI.0000000000000568. PMID: 30998567.
